Remission without disease-modifying antirheumatic drugs has become an ambitious goal in inflammatory rheumatic diseases. While it has been extensively studied in rheumatoid arthritis, its feasibility in psoriatic arthritis (PsA) has remained largely unclear. Dutch researchers have collected data on prevalence, persistence and prognostic factors.
Autoren
- Jens Dehn
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – Sprue
- Case Report
76-year-old patient with pustular skin rash
- Sponsored Content: Psoriasis
Dauerhafte Erscheinungsfreiheit auch bei betroffenen speziellen Hautarealen
- Antithymocyte globulin in children with T1D
Old medicine, new hope
- Ginkgo biloba
Database of preclinical and clinical studies is becoming increasingly larger
- Digital biomarkers
Continuous monitoring using digital biomarkers in MS care
- Benefits, limits and safety aspects
Phytotherapy for cardiovascular diseases
- Results of the FOREST HCM study